Get the Stockscreener App
4.40
1.79%
-0.08
Omeros Corporation stock is traded at $4.40, with a volume of 926.16K.
It is down -1.79% in the last 24 hours and up +17.65% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$4.48
Open:
$4.43
24h Volume:
926.16K
Relative Volume:
0.80
Market Cap:
$271.75M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-2.3404
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-0.23%
1M Performance:
+17.65%
6M Performance:
-52.07%
1Y Performance:
+6.80%
1-Day Range:
$4.36
$4.54
1-Week Range:
$4.035
$4.545
52-Week Range:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
4.40 | 283.61M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Omeros: Deja Vu All Over Again (Rating Downgrade) (NASDAQ:OMER) - Seeking Alpha
Wyckoff Accumulation Phase Possible in Omeros CorporationWeekly Trade Summary & Growth Focused Investment Plans - classian.co.kr
What’s next for Omeros Corporation stockJuly 2025 Review & Verified Technical Trade Signals - kangso.co.kr
Omeros Q2 Earnings Miss Highlight Market Resilience and Rebound Potential - AInvest
Omeros Corp Maintains 'Buy' Rating with $36 Price Target: D. Boral Capital. - AInvest
Needham Maintains Hold Rating on Omeros Stock - AInvest
Omeros Reports Q2 2025 Financial Results, Net Loss Down to $25.4mln - AInvest
What indicators show strength in Omeros CorporationWeekly Loss Report & Community Driven Trade Alerts - Newser
Does Omeros Corporation qualify in momentum factor screeningCPI Data & Weekly Breakout Stock Alerts - Newser
D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Earns Hold Rating from Needham & Company LLC - Defense World
Real time scanner hits for Omeros Corporation explainedJuly 2025 Patterns & Fast Moving Trade Plans - Newser
What are Omeros Corporation’s recent SEC filings showingMarket Trend Summary & Weekly Setup with ROI Potential - thegnnews.com
Omeros Corporation stock daily chart insightsQuarterly Risk Review & Safe Capital Growth Trade Ideas - Newser
Is Omeros Corporation a Top Dividend Stock to Watch in 2025Share Buyback & Weekly Watchlist for Consistent Profits - Newser
Real Time Data Flags Unusual Activity in Omeros Corporation2025 Stock Rankings & Precise Trade Entry Recommendations - newsyoung.net
Omeros: Q2 Earnings Snapshot - Norwalk Hour
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... - Yahoo Finance
Omeros Posts 2,652 Percent Sales Jump - AOL.com
Omeros Corporation Reports Q2 2025 Financial Results - TipRanks
Transcript : Omeros Corporation, Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Earnings call transcript: Omeros beats Q2 2025 EPS forecast, stock dips - Investing.com Canada
Omeros Corporation Reports Second Quarter 2025 Financial Results - Placera.se
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 - MarketScreener
Omeros Corporation to Announce Q2 Financial Results on August 14, 2025 - AInvest
Can Omeros Corporation rally from current levelsShort Term Profit Strategy with Entry Cues - Newser
What makes Omeros Corporation stock price move sharplyDaily Market Momentum and Pressure Analysis - Newser
Omeros Corporation’s Price Action Aligns with Quant SignalsRisk Managed Intraday Trade Alerts Increase in Volume - 선데이타임즈
Press Release: Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 - 富途牛牛
Omeros Announces Q2 2025 Earnings Release and Conference Call on August 14 - AInvest
A&O Shearman advises D. Boral Capital LLC on USD22 million registered direct offering of Omeros Corporation - A&O Shearman
Will earnings trigger a reversal in Omeros CorporationPrice Forecast Based on AI Analysis - Newser
Does Omeros Corporation fit your quant trading modelBuy Candidate Summary Based on Fundamentals - Newser
Volatility clustering patterns for Omeros CorporationFree Exit Ready Momentum Stock Watchlist - Newser
Best data tools to analyze Omeros Corporation stockWeekly Stock Movement Prediction Watchlist - Newser
How institutional ownership impacts Omeros Corporation stockLong-Term Trend Tracking and Signal Summary - Newser
Omeros Corporation shares rise 1.32% premarket after positive investor sentiment in Europe. - AInvest
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Seattle biopharma raises $22 million through stock sale - The Business Journals
Omeros announces pricing of $22 million registered direct offering - MSN
Omeros Corporation Stock Analysis and ForecastGet daily expert analysis for smarter investing - Jammu Links News
What is the dividend policy of Omeros Corporation stockConsistent triple returns - Jammu Links News
Omeros rises after pricing ~$22M stock offering - MSN
What institutional investors are buying Omeros Corporation stockMassive wealth growth - Jammu Links News
How strong is Omeros Corporation company’s balance sheetExceptional trading performance - Jammu Links News
What catalysts could drive Omeros Corporation stock higher in 2025Discover stocks with explosive upside potential - Jammu Links News
Why is Omeros Corporation stock attracting strong analyst attentionFree Stock Movement Tracking - Jammu Links News
How many analysts rate Omeros Corporation as a “Buy”Proven strategies for superior portfolio growth - Jammu Links News
How volatile is Omeros Corporation stock compared to the marketFree Trading Strategy Suggestions - Jammu Links News
When is Omeros Corporation stock expected to show significant growthPhenomenal investment performance - Jammu Links News
Is Omeros Corporation a good long term investmentAchieve rapid portfolio growth with smart picks - Jammu Links News
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):